

CCDC22 Antibody (N-Terminus) Rabbit Polyclonal Antibody Catalog # ALS15636

Specification

CCDC22 Antibody (N-Terminus) - Product Information

| Application | IHC, IF, WB |
|-------------------|---------------|
| Primary Accession | <u>060826</u> |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 71kDa KDa |

CCDC22 Antibody (N-Terminus) - Additional Information

Gene ID 28952

Other Names Coiled-coil domain-containing protein 22, CCDC22, CXorf37

Target/Specificity Human CCDC22. At least three isoforms of CCDC22 are known to exist; this antibody will detect the two largest isoforms.

Reconstitution & Storage Store at -20°C. Aliquot to avoid freeze/thaw cycles.

Precautions CCDC22 Antibody (N-Terminus) is for research use only and not for use in diagnostic or therapeutic procedures.

CCDC22 Antibody (N-Terminus) - Protein Information

Name CCDC22

Synonyms CXorf37

Function

Involved in regulation of NF-kappa-B signaling. Promotes ubiquitination of I-kappa-B-kinase subunit IKBKB and its subsequent proteasomal degradation leading to NF-kappa-B activation; the function may involve association with COMMD8 and a CUL1-dependent E3 ubiquitin ligase complex. May down-regulate NF-kappa-B activity via association with COMMD1 and involving a CUL2-dependent E3 ubiquitin ligase complex. Regulates the cellular localization of COMM domain-containing proteins, such as COMMD1 and COMMD10 (PubMed:23563313). Component of the CCC complex, which is involved in the regulation of endosomal recycling of surface proteins, including integrins, signaling receptor and channels. The CCC complex associates with SNX17, retriever and WASH complexes to prevent lysosomal degradation and promote cell surface



recycling of numerous cargos such as integrins ITGA5:ITGB1 (PubMed:28892079, PubMed:25355947). Plays a role in copper ion homeostasis. Involved in copper-dependent ATP7A trafficking between the trans-Golgi network and vesicles in the cell periphery; the function is proposed to depend on its association within the CCC complex and cooperation with the WASH complex on early endosomes (PubMed:25355947).

Cellular Location

Endosome. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome

Tissue Location

Widely expressed in adult tissues and in fetal liver and brain, with highest levels in prostate and lowest in skeletal muscle.

CCDC22 Antibody (N-Terminus) - Protocols

Provided below are standard protocols that you may find useful for product applications.

- <u>Western Blot</u>
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- <u>Cell Culture</u>

CCDC22 Antibody (N-Terminus) - Images



Anti-CCDC22 antibody IHC staining of human prostate.





Immunofluorescence of CCDC22 in human brain tissue with CCDC22 antibody at 20 ug/ml.



Western blot analysis of CCDC22 in 293 cell lysate with CCDC22 antibody at (A) 1 and (B) 2 ug/ml.

CCDC22 Antibody (N-Terminus) - Background

Involved in regulation of NF-kappa-B signaling. Promotes ubiquitination of I-kappa-B-kinase subunit IKBKB and its subsequent proteasomal degradation leading to NF-kappa-B activation; the function may involve association with COMMD8 and a CUL1-dependent E3 ubiquitin ligase complex. May down-regulate NF- kappa-B activity via assocation with COMMD1 and involving a CUL2- dependent E3 ubiquitin ligase complex. Regulates the cellular localization of COMM domain-containing proteins, such as COMMD1 and COMMD10 (PubMed:23563313). Plays a role in copper ion homeostasis. Involved in copper-dependent ATP7A trafficking between the trans-Golgi network and vesicles in the cell periphery; the function is proposed to depend on its association within the CCC complex and cooperation with the WASH complex on early endosomes (PubMed:25355947).

CCDC22 Antibody (N-Terminus) - References

Strom T.M., et al.Submitted (APR-1998) to the EMBL/GenBank/DDBJ databases. Ota T., et al.Nat. Genet. 36:40-45(2004). Zahedi R.P., et al.J. Proteome Res. 7:526-534(2008). Burkard T.R., et al.BMC Syst. Biol. 5:17-17(2011). Voineagu I., et al.Mol. Psychiatry 17:4-7(2012).